AlphAIAlphAI — Financial news for AI agents
fool.comAUG 203 min read$OPRX

OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript

OptimizeRx (OPRX) reported Q2 2026 revenue of $20.5M, down 30% YoY due to lower-margin services and customer inactivity. Adjusted EBITDA was $4.9M. Full-year guidance was reaffirmed: $95M-$100M revenue and $21M-$25M adjusted EBITDA. AI software revenue grew 25% YoY. Cash and cash equivalents were $24.1M, with debt reduced to $19.7M. Management highlighted strategic shifts and leadership transitions. (350 characters)

Original reporting
fool.com
Published Aug 20, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$OPRXBullishMed
01

Why it matters

Earnings beat and reaffirmed guidance suggest the transition is progressing, but revenue contraction and customer concentration remain risks.

02

Market read

Micro‑cap healthcare‑tech stock with fresh earnings data; relevant for short‑term traders and sector specialists.

03

What to watch

Debt repayment schedule and upcoming CFO transition may affect near‑term liquidity.

Relevance 6/10Novelty 8/10Timing: post‑earnings Q2 2026 release

Background

OptimizeRx is transitioning from low‑margin managed services to higher‑margin AI software for pharma marketers.

Company-level read

Ticker impact

$OPRXBullishHigh confidence
Context

Q2 2026 earnings release with revenue $20.5M, adjusted EBITDA $4.9M, and reaffirmed full-year guidance.

Expected impact

Potential short-term upside as investors digest beat and guidance.

Evidence & confidence

First report of earnings numbers and guidance for a micro‑cap; beat and reaffirmation are actionable.

Market effects

Sector

Highlights AI‑enabled software growth in healthcare advertising sector.

Regional

US healthcare tech niche may see modest re‑rating.

Global

Limited to investors tracking niche pharma‑tech firms.

Counterpoint

What could challenge this read

Revenue decline and high customer concentration could pressure the stock despite earnings beat.

Key entities

  • Executive
    Stephen L. Silvestro

    CEO of OptimizeRx

  • Executive
    Edward Stelmakh

    Chief Financial Strategy Officer, soon to be CFO successor

Read at source← All news

Related articles

AUG 12
$OPRXMed

OptimizeRx Corp (OPRX): Results of Operations and Financial Condition

OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q2 revenue totals $20.5 million - Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively - Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million

SEC EDGAR 8-K4 min
SEP 22
$AZOMedAI 8/10

AutoZone Q4 EPS Hits $56.05 as Annual Sales Reach $20.3bn

AutoZone (AZO) reported Q4 2026 EPS of $56.05, up from $48.71 a year earlier, with net sales of $6.6bn, a 5.6% increase. Full-year sales reached $20.3bn, up 7.4%. Gross margin rose to 53.3%, boosted by tariff refunds and LIFO benefits. The company opened 175 new stores, ending the year with 8,031 locations. Shares rose 4.33% post-earnings.

financial-news.co.uk2 min
SEP 22
$AZOHighAI 8/10

Why AutoZone (AZO) Stock Is Trading Up Today

AutoZone (AZO) shares rose 6.1% after reporting Q4 EPS of $56.05, beating estimates. Net sales were $6.6B, missing expectations. Same-store sales grew 1.6%, and gross margin expanded 182 bps to 53.3%. The company's stock has had limited volatility, with today's move being notable. AZO is down 9.9% YTD, trading 30.6% below its 52-week high.

financialcontent.com2 min
SEP 22
$AMGNMedAI 8/10

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data - Amgen (NA

Amgen (AMGN) reported positive results from its Phase 3 OASIZ 301 trial for dazodalibep in treating Sjögren’s disease, meeting the primary endpoint. The study showed statistically significant improvements in disease activity scores. Adverse events were low and similar to placebo. Amgen plans to share full data at a future conference and awaits results from another trial, OASIZ 303, for potential FDA filing. Shares rose 3.54% to $407.08. Analysts expect two positive trials for approval.

benzinga.com4 min